Clinical trials: Advanced Solid Tumors Patients
Advanced Solid Tumor
Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients
This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on the PK of bupropion and warfarin patients with advanced solid tumors.
- Trial name
- NCT01769768
- Testing
- LDE225, Wafarin, Bupropion
- Where
- 13 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Solid Tumors, Relapsed/Refractory B-cell Lymphoma
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma.
- Trial name
- NCT06445517
- Testing
- ISM8207
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Tumors
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.
- Trial name
- NCT00412789
- Testing
- Patupilone
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Solid Tumor
ALG.APV-527 First-in-human Study
A first-in-human, multicenter, open-label, dose escalation and dose expansion phase 1 study in patients with advanced solid tumors to evaluate the safety of intravenously administered ALG.APV-527 (Short title: ALG.APV-527…
- Trial name
- NCT05934539
- Testing
- ALG.APV-527
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Aptevo Therapeutics
Solid Tumors
A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors
The purpose of this study is to determine whether treatment with necitumumab monotherapy affects the QT/QTc interval among participants with advanced solid tumors refractory to standard treatment or for which no standard…
- Trial name
- NCT01624467
- Testing
- Necitumumab
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Solid Tumors Harboring a BRAF V600 Mutation
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
This is a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate the MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and the triple combination of LGX818 and MEK162 and LEE011…
- Trial name
- NCT01543698
- Testing
- LGX818, MEK162, LEE011
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 189 people
- Sponsor
- Pfizer
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Advanced Cancer, Advanced Solid Tumor
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05525455
- Testing
- TT-816, A PD-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Teon Therapeutics, Inc.
Advanced Solid Tumor
A Study of KL590586 in Patients With Advanced Solid Tumors
An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of KL590586 Capsules In Patients With Advanced Solid Tumors Carrying RET Fusion Or Mutant…
- Trial name
- NCT05265091
- Testing
- KL590586 Capsule
- Where
- China
- Volunteers
- 414 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Neoplasms
A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer
The primary objective of this trial is: Part I To determine Maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BI 836880 monotherapy Part II To determine MTD and/or RP2D of the combination therapy of BI 836880…
- Trial name
- NCT03972150
- Testing
- BI 836880, BI 754091
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase I study to assess the effects of dovitinib (TKI258) on the pharmacokinetics of a cocktail of caffeine, diclofenac, omeprazole and midazolam in patients with advanced solid tumors…
- Trial name
- NCT01596647
- Testing
- caffeine, diclofenac, omeprazole
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
NTRK Fusion-positive Solid Tumors
Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan
This study will collect safety information during routine medical care for children and adolescents in Japan who have been diagnosed with NTRK fusion-positive advanced or recurrent solid tumors who start treatment with…
- Trial name
- NCT07755826
- Testing
- Repotrectinib
- Where
- 2 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Non-Hodgkin Lymphoma
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
- Trial name
- NCT05221385
- Testing
- Gentulizumab
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Neoplasms
BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors
Maximum tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic parameters, and efficacy of pulsatile administration of BIBW 2992 in combination with docetaxel (Taxotere®)
- Trial name
- NCT02171676
- Testing
- Docetaxel, BIBW 2992
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
This is a multicenter, open-label, phase Ib/II study on the efficacy and safety of F520 combined with lenvatinib in the treatment of patients with advanced solid tumors.
- Trial name
- NCT05740215
- Testing
- F520, Lenvatinib
- Where
- China
- Volunteers
- 158 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.